Recently, Kim et al. 52 demonstrated that leukemia stem cells from de novo AML patients can induce extensive alterations in the mesenchymal niche, resulting in an altered expression of crosstalk molecules, including CXCL12. This evidence concerns the gene CXCL12 and leukemia.